Developing Cutting Edge Life-Saving CAR-T Therapies for Systemic Lupus Erythematosus (SLE) Patients

Time: 9:50 am
day: Conference Day Two


  • Developing a compound chimeric antigen receptor (cCAR) targeting both CD19 and BCMA to exert more comprehensive killing and prevent antigen escape
  • Sharing clinical data and long-term outcomes, with the first patient being administered over 4 years ago
  • Demonstrating well tolerated, long-term remission in a single administration